Cada Dennis J, Levien Terri L, Baker Danial E
Founder and Contributing Editor, The Formulary , Washington State University , Spokane, Washington.
Clinical Professor, College of Pharmacy, Washington State University , Spokane, Washington.
Hosp Pharm. 2015 Jan;50(1):59-71. doi: 10.1310/hpj5001-59.
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are sent in print and are also available on-line. Monographs can be customized to meet the needs of a facility. A drug class review is now published monthly with The Formulary Monograph Service. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, call The Formulary at 800-322-4349. The January 2015 monograph topics are ledipasvir/sofosbuvir, eliglustat, naloxegol, pembrolizumab, and dulaglutide injection. The Safety MUE is on ledipasvir/sofosbuvir.
每月，《处方集专论服务》的订阅者会收到5至6篇关于新发布或处于3期临床试验后期的药物的详细专论。这些专论面向药学与治疗学委员会。订阅者每月还会收到关于对议程以及药房/护理在职培训有用的药物的1页摘要专论。每月还会提供一份全面的目标药物利用评估/用药使用评估（DUE/MUE）。订阅后，专论将以印刷形式发送，也可在线获取。专论可根据机构需求进行定制。现在每月会随《处方集专论服务》发布一份药物类别综述。通过《处方集》的合作，《医院药学》在本专栏发表精选综述。如需了解更多关于《处方集专论服务》的信息，请致电《处方集》800 - 322 - 4349。2015年1月专论主题包括来迪派韦/索磷布韦、依格列斯他、纳洛西醇、派姆单抗和度拉鲁肽注射液。安全性MUE针对来迪派韦/索磷布韦。
